1345515-22-1 Usage
Description
1-(3-hydroxy-2-methylquinolin-4-yl)ethanone is a chemical compound that belongs to the class of organic compounds known as quinolines and their derivatives. It features a unique structure with a 2-methylquinolin-4-yl group attached to an ethanone moiety at the 1-position, and a hydroxy group on the 3-position of the quinoline ring. 1-(3-hydroxy-2-methylquinolin-4-yl)ethanone is soluble in most organic solvents and can be synthesized in laboratories. Although it does not have extensive applications, it is primarily used in scientific research.
Uses
Used in Scientific Research:
1-(3-hydroxy-2-methylquinolin-4-yl)ethanone is used as a research compound for [application reason] in the field of [specific scientific research area, if known]. Its unique structure and properties make it a valuable tool for studying various chemical and biological processes.
Used in Organic Synthesis:
1-(3-hydroxy-2-methylquinolin-4-yl)ethanone is used as a synthetic intermediate for the preparation of other quinolines and their derivatives. Its reactivity and functional groups allow for further chemical modifications and the development of new compounds with potential applications in various industries.
Used in Pharmaceutical Development:
Although not extensively used, 1-(3-hydroxy-2-methylquinolin-4-yl)ethanone may have potential applications in the pharmaceutical industry. Its unique structure could be explored for the development of new drugs targeting specific biological pathways or diseases.
Used in Chemical Analysis:
1-(3-hydroxy-2-methylquinolin-4-yl)ethanone can be used as a reference compound or standard in chemical analysis and testing. Its solubility in organic solvents and unique properties make it suitable for various analytical techniques, such as chromatography, spectroscopy, and titration.
Check Digit Verification of cas no
The CAS Registry Mumber 1345515-22-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,4,5,5,1 and 5 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1345515-22:
(9*1)+(8*3)+(7*4)+(6*5)+(5*5)+(4*1)+(3*5)+(2*2)+(1*2)=141
141 % 10 = 1
So 1345515-22-1 is a valid CAS Registry Number.
1345515-22-1Relevant articles and documents
Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor
Neelamkavil, Santhosh F.,Agrawal, Sony,Bara, Thomas,Bennett, Chad,Bhat, Sathesh,Biswas, Dipshikha,Brockunier, Linda,Buist, Nicole,Burnette, Duane,Cartwright, Mark,Chackalamannil, Samuel,Chase, Robert,Chelliah, Mariappan,Chen, Austin,Clasby, Martin,Colandrea, Vincent J.,Davies, Ian W.,Eagen, Keith,Guo, Zhuyan,Han, Yongxin,Howe, John,Jayne, Charles,Josien, Hubert,Kargman, Stacia,Marcantonio, Karen,Miao, Shouwu,Miller, Randy,Nolting, Andrew,Pinto, Patrick,Rajagopalan, Murali,Ruck, Rebecca T.,Shah, Unmesh,Soriano, Aileen,Sperbeck, Donald,Velazquez, Francisco,Wu, Jin,Xia, Yan,Venkatraman, Srikanth
, p. 111 - 116 (2016/02/03)
We have been focused on identifying a structurally different next generation inhibitor to MK-5172 (our Ns3/4a protease inhibitor currently under regulatory review), which would achieve superior pangenotypic activity with acceptable safety and pharmacokinetic profile. These efforts have led to the discovery of a novel class of HCV NS3/4a protease inhibitors containing a unique spirocyclic-proline structural motif. The design strategy involved a molecular-modeling based approach, and the optimization efforts on the series to obtain pan-genotypic coverage with good exposures on oral dosing. One of the key elements in this effort was the spirocyclization of the P2 quinoline group, which rigidified and constrained the binding conformation to provide a novel core. A second focus of the team was also to improve the activity against genotype 3a and the key mutant variants of genotype 1b. The rational application of structural chemistry with molecular modeling guided the design and optimization of the structure-activity relationships have resulted in the identification of the clinical candidate MK-8831 with excellent pan-genotypic activity and safety profile.
